Abstract: A stent (32) configured to be placed in a body lumen and having a tubular shape formed by a structure that is expandable and contractible skeleton (18, 19) in a radial direction, the skeleton (18, 19) having a heteromorphic structure due to changes of a cross section shape thereof in a thickness direction. A stent (10) that is expandable and contractible in the radial direction while being configured to be placed in a body lumen, the stent (10) having a heteromorphic tubular shape, a cross section shape of which changes in a lengthwise direction, and having a metal skeleton (18, 19) formed by at least one of electroforming and etching.

Abstract: A stent (32) configured to be placed in a body lumen and having a tubular shape formed by a structure that is expandable and contractible skeleton (18, 19) in a radial direction, the skeleton (18, 19) having a heteromorphic structure due to changes of a cross section shape thereof in a thickness direction. A stent (10) that is expandable and contractible in the radial direction while being configured to be placed in a body lumen, the stent (10) having a heteromorphic tubular shape, a cross section shape of which changes in a lengthwise direction, and having a metal skeleton (18, 19) formed by at least one of electroforming and etching.

Abstract: A stent (32) configured to be placed in a body lumen and having a tubular shape formed by a structure that is expandable and contractible skeleton (18, 19) in a radial direction, the skeleton (18, 19) having a heteromorphic structure due to changes of a cross section shape thereof in a thickness direction. A stent (10) that is expandable and contractible in the radial direction while being configured to be placed in a body lumen, the stent (10) having a heteromorphic tubular shape, a cross section shape of which changes in a lengthwise direction, and having a metal skeleton (18, 19) formed by at least one of electroforming and etching.

Abstract: Novel diphenylmethyl piperazine derivatives of this invention have a chemical structure represented by the following Formula [I]: ##STR1## wherein R represents ##STR2## The compounds have an effect of inhibiting the overcontraction and overextension of the myocardium without being accompanied by a myocardium-inhibiting effect. By using the novel diphenylmethyl piperazine derivatives as an effective ingredient, it is possible to obtain a myocardial necrosis inhibitor which can protect against myocardial necrosis, and a drug for the treatment and prevention of acute myocardial infarction.